Richard Kunze

Richard Kunze

Auto-generated profile, based on publicly available information

Richard Kunze

Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in mAbs
Verified
Journal Article
Open access
RKRichard Kunze
Richard Kunze
FNFabian Navratil
Fabian Navratil
JBJoana Beichert
Joana Beichert
FGFelix Geyer
Felix Geyer
DFDoreen M. Floss
Doreen M. Floss
SPSilke Pudewell
Silke Pudewell
Nanobodies are small, single-domain antibody fragments derived from heavy chain - only antibodies. They combine high binding affinity with advantages such as compact size, stability, solubility, and flexible epitope recognition, making them attractive tools in molecular biology and therapeutic applications. In this study, we engineered and optimized nanobodies for controlled activation of synthetic cytokine receptors, aiming to expand options for receptor customization. Specifically, we used nanobodies as extracellular domains of the gp130 receptor to induce dimerization upon antigen binding. To enable receptor activity, we introduced framework mutations that promote the formation of an i-shaped nanobody (iBody) dimer, adapted from i-shaped antibodies. These mutations enhanced dimerization and enabled low-level ligand-independent receptor activation. AlphaFold modeling identified the key amino acids responsible for forming the iBody interface. Additional modifications reduced intermolecular affinity, thereby minimizing background activation while preserving the structural features necessary for ligand-induced stimulation. This approach effectively broadened the receptor's activation range. Importantly, these framework mutations were not limited to the gp130-specific nanobody GP11 but were also functional in AIP3, an anti-idiotypic nanobody targeting palivizumab. Here, the modified nanobody fusion receptor could be activated by palivizumab, overcoming prior steric hindrance.